The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide

P. Raskin, R. Guthrie, J. M. Flack, R. A. Reeves, Ravi Saini

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The long-term safety, tolerability, and antihypertensive effects of irbesartan/hydrochlorothiazide (HCTZ) were assessed in hypertensive patients (seated diastolic blood pressure [SeDBP] 95-110 mmHg). Patients (n = 1098) completing two randomised, double-blind trials of irbesartan alone, HCTZ alone, irbesartan/HCTZ combinations, or placebo, took year of open-label therapy starting with irbesartan 75 mg/HCTZ 12.5 mg once daily. If target blood pressure (BP) (<140/<90 mmHg) was not achieved, the dose was titrated sequentially at 2- to 4-week intervals to irbesartan 150 mg/HCTZ 12.5mg, then to irbesartan 300mg/HCTZ 25mg. If necessary, adjunctive therapies were added. Mean changes in trough seated systolic BP/SeDBP at months 2, 6, and 12 were -19.1/-14.2 mmHg (n = 941), -20.7/ -15.7 mmHg (n = 948), and -20.6/-15.6 mmHg (n = 898), respectively. From months 2 to 12, normalisation rates (trough SeDBP < 90 mmHg) ranged from 75-85% and total responder rates (normalised or ≥ 10 mm Hg trough SeDBP reduction) ranged from 81-91%, while target BP was achieved in 65-75% of patients. At all time-points, most patients (≥ 87%) were receiving irbesartan/HCTZ alone. Eighty-two patients (7.5%) discontinued the study due to adverse events, with half of these events considered unrelated to study medication. There were no reports of serious adverse events related to study medication. Long-term therapy with irbesartan/HCTZ is safe, well tolerated, and maintains normalised BP in > 80% of patients.

Original languageEnglish (US)
Pages (from-to)683-687
Number of pages5
JournalJournal of Human Hypertension
Volume13
Issue number10
StatePublished - 1999

Fingerprint

irbesartan
Hydrochlorothiazide
Antihypertensive Agents
Blood Pressure
Placebos
Safety

Keywords

  • Angiotensin II receptor antagonist
  • Combination therapy
  • Diuretic
  • Hydrochlorothiazide
  • Irbesartan

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. / Raskin, P.; Guthrie, R.; Flack, J. M.; Reeves, R. A.; Saini, Ravi.

In: Journal of Human Hypertension, Vol. 13, No. 10, 1999, p. 683-687.

Research output: Contribution to journalArticle

Raskin, P. ; Guthrie, R. ; Flack, J. M. ; Reeves, R. A. ; Saini, Ravi. / The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. In: Journal of Human Hypertension. 1999 ; Vol. 13, No. 10. pp. 683-687.
@article{4c9bf815bb5b46d2868dc7f84f59cf6a,
title = "The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide",
abstract = "The long-term safety, tolerability, and antihypertensive effects of irbesartan/hydrochlorothiazide (HCTZ) were assessed in hypertensive patients (seated diastolic blood pressure [SeDBP] 95-110 mmHg). Patients (n = 1098) completing two randomised, double-blind trials of irbesartan alone, HCTZ alone, irbesartan/HCTZ combinations, or placebo, took year of open-label therapy starting with irbesartan 75 mg/HCTZ 12.5 mg once daily. If target blood pressure (BP) (<140/<90 mmHg) was not achieved, the dose was titrated sequentially at 2- to 4-week intervals to irbesartan 150 mg/HCTZ 12.5mg, then to irbesartan 300mg/HCTZ 25mg. If necessary, adjunctive therapies were added. Mean changes in trough seated systolic BP/SeDBP at months 2, 6, and 12 were -19.1/-14.2 mmHg (n = 941), -20.7/ -15.7 mmHg (n = 948), and -20.6/-15.6 mmHg (n = 898), respectively. From months 2 to 12, normalisation rates (trough SeDBP < 90 mmHg) ranged from 75-85{\%} and total responder rates (normalised or ≥ 10 mm Hg trough SeDBP reduction) ranged from 81-91{\%}, while target BP was achieved in 65-75{\%} of patients. At all time-points, most patients (≥ 87{\%}) were receiving irbesartan/HCTZ alone. Eighty-two patients (7.5{\%}) discontinued the study due to adverse events, with half of these events considered unrelated to study medication. There were no reports of serious adverse events related to study medication. Long-term therapy with irbesartan/HCTZ is safe, well tolerated, and maintains normalised BP in > 80{\%} of patients.",
keywords = "Angiotensin II receptor antagonist, Combination therapy, Diuretic, Hydrochlorothiazide, Irbesartan",
author = "P. Raskin and R. Guthrie and Flack, {J. M.} and Reeves, {R. A.} and Ravi Saini",
year = "1999",
language = "English (US)",
volume = "13",
pages = "683--687",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide

AU - Raskin, P.

AU - Guthrie, R.

AU - Flack, J. M.

AU - Reeves, R. A.

AU - Saini, Ravi

PY - 1999

Y1 - 1999

N2 - The long-term safety, tolerability, and antihypertensive effects of irbesartan/hydrochlorothiazide (HCTZ) were assessed in hypertensive patients (seated diastolic blood pressure [SeDBP] 95-110 mmHg). Patients (n = 1098) completing two randomised, double-blind trials of irbesartan alone, HCTZ alone, irbesartan/HCTZ combinations, or placebo, took year of open-label therapy starting with irbesartan 75 mg/HCTZ 12.5 mg once daily. If target blood pressure (BP) (<140/<90 mmHg) was not achieved, the dose was titrated sequentially at 2- to 4-week intervals to irbesartan 150 mg/HCTZ 12.5mg, then to irbesartan 300mg/HCTZ 25mg. If necessary, adjunctive therapies were added. Mean changes in trough seated systolic BP/SeDBP at months 2, 6, and 12 were -19.1/-14.2 mmHg (n = 941), -20.7/ -15.7 mmHg (n = 948), and -20.6/-15.6 mmHg (n = 898), respectively. From months 2 to 12, normalisation rates (trough SeDBP < 90 mmHg) ranged from 75-85% and total responder rates (normalised or ≥ 10 mm Hg trough SeDBP reduction) ranged from 81-91%, while target BP was achieved in 65-75% of patients. At all time-points, most patients (≥ 87%) were receiving irbesartan/HCTZ alone. Eighty-two patients (7.5%) discontinued the study due to adverse events, with half of these events considered unrelated to study medication. There were no reports of serious adverse events related to study medication. Long-term therapy with irbesartan/HCTZ is safe, well tolerated, and maintains normalised BP in > 80% of patients.

AB - The long-term safety, tolerability, and antihypertensive effects of irbesartan/hydrochlorothiazide (HCTZ) were assessed in hypertensive patients (seated diastolic blood pressure [SeDBP] 95-110 mmHg). Patients (n = 1098) completing two randomised, double-blind trials of irbesartan alone, HCTZ alone, irbesartan/HCTZ combinations, or placebo, took year of open-label therapy starting with irbesartan 75 mg/HCTZ 12.5 mg once daily. If target blood pressure (BP) (<140/<90 mmHg) was not achieved, the dose was titrated sequentially at 2- to 4-week intervals to irbesartan 150 mg/HCTZ 12.5mg, then to irbesartan 300mg/HCTZ 25mg. If necessary, adjunctive therapies were added. Mean changes in trough seated systolic BP/SeDBP at months 2, 6, and 12 were -19.1/-14.2 mmHg (n = 941), -20.7/ -15.7 mmHg (n = 948), and -20.6/-15.6 mmHg (n = 898), respectively. From months 2 to 12, normalisation rates (trough SeDBP < 90 mmHg) ranged from 75-85% and total responder rates (normalised or ≥ 10 mm Hg trough SeDBP reduction) ranged from 81-91%, while target BP was achieved in 65-75% of patients. At all time-points, most patients (≥ 87%) were receiving irbesartan/HCTZ alone. Eighty-two patients (7.5%) discontinued the study due to adverse events, with half of these events considered unrelated to study medication. There were no reports of serious adverse events related to study medication. Long-term therapy with irbesartan/HCTZ is safe, well tolerated, and maintains normalised BP in > 80% of patients.

KW - Angiotensin II receptor antagonist

KW - Combination therapy

KW - Diuretic

KW - Hydrochlorothiazide

KW - Irbesartan

UR - http://www.scopus.com/inward/record.url?scp=0032873967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032873967&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 683

EP - 687

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - 10

ER -